The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
Primary Purpose
Cognition, Gut Microbiome
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Probiotic Supplement
Transcutaneous Vagal Nerve Stimulation (tVNS)
Sponsored by

About this trial
This is an interventional basic science trial for Cognition
Eligibility Criteria
Inclusion Criteria:
- Age 35-70 years
- English or Spanish speaking
- Alcohol users
- Cognitive impairment
- Current CD4>350
Exclusion Criteria:
- Diagnosed major psychiatric illness
- Consumption of over 300 drinks in the past 30 days
- Recent opioid use
- Lifetime history of medically-assisted alcohol detoxification
- Inpatient or intensive treatment for addictive behaviors in the past 12 months
- MRI contraindications
- Current antibiotic treatment
- Current probiotic use
- Physical impairment precluding motor response or lying still.
Sites / Locations
- University of MiamiRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Dietary Supplement (e.g., vitamins, minerals)
Device (including sham)
Arm Description
Visbiome probiotic supplement
Transcutaneous Vagal Nerve Stimulation (tVNS)
Outcomes
Primary Outcome Measures
Improved cognition from day 1 to day 90
Various indices of cognition will be measured using standard neuropsychological tests and neuroimaging at multiple time points and examined for change within subjects.
Reduction of dysbiosis from day 1 to day 90
The gut microbiome will be analyzed through stool samples to measure for changes in biodiversity including an increase in beneficial bacteria.
Secondary Outcome Measures
Full Information
NCT ID
NCT05090267
First Posted
September 21, 2021
Last Updated
July 5, 2022
Sponsor
University of Florida
Collaborators
University of Miami, University of Louisville, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Exegi Pharma, LLC, Soterix Medical
1. Study Identification
Unique Protocol Identification Number
NCT05090267
Brief Title
The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
Official Title
Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2022 (Actual)
Primary Completion Date
June 30, 2026 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Florida
Collaborators
University of Miami, University of Louisville, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Exegi Pharma, LLC, Soterix Medical
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This project uses a hybrid trial design to evaluate two biomedical interventions targeting the gut-brain axis. One intervention is portable Transcutaneous Vagus Nerve Stimulator, tVNS, that is hypothesized to stimulate the autonomic nervous system, resulting in decreased inflammation and improved cognition. The second intervention is a probiotic supplement intended to replace gut bacteria that are associated with dysbiosis in persons with HIV and alcohol consumption.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognition, Gut Microbiome
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Model Description
This is a 2 x 2 factorial, longitudinal design (tVNS/Sham, Probiotic/Placebo) across three time points (baseline; 30days and 90days).
Masking
ParticipantInvestigator
Masking Description
This is a 2x2 design in which subjects will be randomly assigned to one of 4 interventions groups: tVNS and probiotic (n=20); tVNS and placebo (n=20), sham stimulator and probiotic (n=20), and sham stimulator and placebo (n=20). We will use a computer-assisted stratified block randomization with block size of 4 to assign participants to the intervention. Study participants, investigators, staff, and physicians administering the probiotics or placebo will be unaware of specific group assignment. The stratified, blocked randomization and assignment of participants to the 4 intervention groups will be guided and monitored by Data Science Core.
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Dietary Supplement (e.g., vitamins, minerals)
Arm Type
Experimental
Arm Description
Visbiome probiotic supplement
Arm Title
Device (including sham)
Arm Type
Active Comparator
Arm Description
Transcutaneous Vagal Nerve Stimulation (tVNS)
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic Supplement
Intervention Description
Participants will take a probiotic supplement or placebo for 90 days.
Intervention Type
Device
Intervention Name(s)
Transcutaneous Vagal Nerve Stimulation (tVNS)
Intervention Description
Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
Primary Outcome Measure Information:
Title
Improved cognition from day 1 to day 90
Description
Various indices of cognition will be measured using standard neuropsychological tests and neuroimaging at multiple time points and examined for change within subjects.
Time Frame
Baseline up to 90 days
Title
Reduction of dysbiosis from day 1 to day 90
Description
The gut microbiome will be analyzed through stool samples to measure for changes in biodiversity including an increase in beneficial bacteria.
Time Frame
Baseline up to 90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 35-70 years
English or Spanish speaking
Alcohol users
Cognitive impairment
Current CD4>350
Exclusion Criteria:
Diagnosed major psychiatric illness
Consumption of over 300 drinks in the past 30 days
Recent opioid use
Lifetime history of medically-assisted alcohol detoxification
Inpatient or intensive treatment for addictive behaviors in the past 12 months
MRI contraindications
Current antibiotic treatment
Current probiotic use
Physical impairment precluding motor response or lying still.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Taylor LeCorgne
Phone
352-273-9562
Email
tlecorgne@ufl.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric Porges, PhD
Organizational Affiliation
University of Florida
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert L Cook, MD
Organizational Affiliation
University of Florida
Official's Role
Study Director
Facility Information:
Facility Name
University of Miami
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33146
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Varan Govind, PhD
Phone
305-243-8096
Email
vgovind@umail.miami.edu
First Name & Middle Initial & Last Name & Degree
Varan Govind, PhD
12. IPD Sharing Statement
Learn more about this trial
The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
We'll reach out to this number within 24 hrs